Clinical trials: Progesterone, open to volunteers
Solid Tumor, Advanced Solid Tumor
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for…
- Conditions
- Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
- Trial name
- NCT06586957
- Testing
- NKT3964, Paclitaxel, Doxorubicin
- Where
- 20 sites in United States, South Korea
- Volunteers
- 238 people
- Sponsor
- NiKang Therapeutics, Inc.
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body.
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive
- Trial name
- NCT03723928
- Testing
- Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment
- Where
- 723 sites in United States, Guam and 1 more
- Volunteers
- 739 people
- Sponsor
- SWOG Cancer Research Network
HER2-positive Breast Cancer, Metastatic Cancer
PRE-ISPY Phase I/II Oncology Platform Program
PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced…
- Conditions
- HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic
- Trial name
- PRE-ISPY (NCT05868226)
- Testing
- ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab
- Where
- 10 sites in United States
- Volunteers
- 280 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Estrogen Receptor Negative, HER2 Positive Breast Carcinoma
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
This clinical trial studies eliminating surgery and/or radiation therapy in treating breast cancer patients. In HER2 positive and triple negative breast cancers, after systemic therapy, when image-guided biopsy shows no residual…
- Conditions
- Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
- Trial name
- NCT02945579
- Testing
- Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 8 sites in United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Neoplasms, Atypical Endometrial Hyperplasia
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.
- Conditions
- Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance
- Trial name
- NCT05316935
- Testing
- GnRHa, Letrozole 2.5mg, Diane-35
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Xiaojun Chen
Endometrial Neoplasms, Atypical Endometrial Hyperplasia
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.
- Conditions
- Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
- Trial name
- NCT06379113
- Testing
- GnRH antagonist, Letrozole 2.5mg
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Xiaojun Chen
Luteal Phase Insuffiency, Progesterone Delivery
First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency
The aim of this clinical trial is to assess safety of a new vaginal 400mg progesterone drug-device combination product in a first in human trial.
- Trial name
- FREEDOM (NCT07136922)
- Testing
- 400mg progesterone Callavid - 2hr wear, Cyclogest 400 mg, 400mg progesterone Callavid - 3hr wear
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Calla Lily Clinical Care Ltd
Menstrual Cycle, Luteal Phase Progesterone Levels
Corpus Luteum Function and Cardiovascular Adaptation in a Natural MOCK Cycle.
In infertility treatment, embryos are created in vitro after eggs have been fertilised by sperm using in vitro fertilisation or intracytoplasmic sperm injection techniques.
- Conditions
- Menstrual Cycle, Luteal Phase Progesterone Levels, Luteal Phase Adaptation, MOCK Cycle
- Trial name
- CLEAR (NCT07648381)
- Testing
- Blood samples for the analysis of biomarkers., Transvaginal ultrasound for follicle and endometrium measurements., Mean Arterial Pressure measurement.
- Where
- Belgium
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Pregnancy, Progesterone Supplementation
Individualized Prolonged Luteal Support After Fresh Embryo Transfer in Women With Low Progesterone
The goal of this clinical trial is to compare live birth rate in a control group versus an interventional group in subjects aged 18 to 37, pregnant after a fresh embryo transfer and with a serum progesterone level below 17 ng/mL…
- Conditions
- Pregnancy, Progesterone Supplementation, Low Serum Progesterone
- Trial name
- ProLIS (NCT07613528)
- Testing
- Progesterone Injectable, Progesterone Vaginal Suppository
- Where
- France
- Volunteers
- 214 people
- Sponsor
- University Hospital, Montpellier
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT06401889
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Low Dose, Progesterone
Role of Low Dose Injectable Progesterone in Triggering Ovulation
The aim of this study is to evaluate the role of low dose injectable progesterone in triggering ovulation.
- Conditions
- Low Dose, Progesterone, Triggering Ovulation
- Trial name
- NCT06928844
- Testing
- Progesterone
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- The General Authority for Teaching Hospitals and Institutes
Endometriosis
Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy
This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy.
- Trial name
- ENDOmiRNA (NCT06414720)
- Testing
- Dienogest 2 MG
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- University of Udine